Lepu Biopharma has granted ArriVent Exclusive License for MRG007, a Potential Best-in-Class ADC for the treatment of Gastrointestinal Cancers
HONG KONG, Jan. 22, 2025 /PRNewswire/ -- Today, Lepu Biopharma Co., Ltd (Stock Code: 02157.HK) announced that it has entered into an exclusive licensing agreement withArriVent BioPharma, Inc. for MRG007, a Potential Best-in-Class antibody- drug conjugate ("ADC") for the treatment of Gastrointesti...
2025-01-22 12:19
4418
Lepu Biopharma and Keymed Jointly Announces Global Exclusive Licence Agreement with AstraZeneca for CMG901
HONG KONG, Feb. 22, 2023 /PRNewswire/ -- Lepu Biopharma Co., Ltd. (Stock Code: 02157.HK) and Keymed Biosciences Inc., ("Keymed") (Stock Code: 02162 HK) today jointly announces a global exclusive licence agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for CMG901, a potential first-in-class Claudi...
2023-02-23 12:26
3023
